Correspondence 0001213900-23-076383 from Clearmind Medicine Inc. (CMND)
Clearmind Medicine Inc.
Date: Sept. 13, 2023 · CIK: 0001892500 · Accession: 0001213900-23-076383
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273293
Letter
Clearmind Medicine Inc.
101 – 1220 West 6th Avenue
Vancouver, British Columbia V6H1A5
September 13, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
RE: Clearmind Medicine Inc. (CIK: 0001892500)
Registration Statement No. 333-273293 on Form F-1 (the “Registration Statement”)
Ladies and Gentlemen:
Clearmind Medicine Inc. (the “Registrant”) hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may become effective on September 14, 2023 at 9:00 a.m., Eastern Time, or as soon thereafter as is practicable.
The Registrant understands that the Securities and Exchange Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act as they relate to the proposed public offering of the securities specified in the Registration Statement.
The Registrant respectfully requests that it be notified of such effectiveness by a telephone call to David Huberman, Esq. of Greenberg Traurig, P.A. at (312) 364-1633 and that such effectiveness also be confirmed in writing.
Very truly yours,
Clearmind Medicine Inc.
Show Raw Text
CORRESP
1
filename1.htm
Clearmind Medicine Inc.
101 – 1220 West 6th Avenue
Vancouver, British Columbia V6H1A5
September 13, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
RE:
Clearmind Medicine Inc. (CIK: 0001892500)
Registration Statement No. 333-273293 on Form F-1 (the “Registration Statement”)
Ladies and Gentlemen:
Clearmind Medicine Inc. (the “Registrant”)
hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities
Act of 1933, as amended (the “Securities Act”), so that it may become effective on September 14, 2023 at 9:00 a.m.,
Eastern Time, or as soon thereafter as is practicable.
The Registrant understands that
the Securities and Exchange Commission will consider this request for acceleration of the effective date of the Registration Statement
as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act as they relate to the proposed
public offering of the securities specified in the Registration Statement.
The Registrant respectfully requests
that it be notified of such effectiveness by a telephone call to David Huberman, Esq. of Greenberg Traurig, P.A. at (312) 364-1633 and
that such effectiveness also be confirmed in writing.
Very truly yours,
Clearmind Medicine Inc.
By:
/s/ Dr. Adi Zuloff-Shani
Dr. Adi Zuloff-Shani
Chief Executive Officer